One lab, from extraction to interpretation.
NCRO runs molecular diagnostics, PCR, Sanger & NGS sequencing, cell-based bioassays and bioinformatics for research, healthcare, biopharma and agrifood clients — with in-house library prep, PhD-level review, and reports built to be acted on.
Serving research institutions, hospitals & clinical labs, biopharma/biotech and agrifood industries across Pakistan.
A team built for the hard cases
Our core team carries a collective 30+ years of experience in biotechnology, NGS and genomics. Eight scientists hold advanced degrees spanning MBBS, PhD, FCPS, DVM and MPhil — clinical, veterinary and research backgrounds working the same bench.
Core laboratory capabilities
Eight service lines under one roof — sample prep through to clinical interpretation.
Molecular Diagnostics & PCR
Conventional, multiplex & real-time qPCR, HRM, gene-expression panels and AMR gene panels.
Sanger Sequencing
16S/ITS genotyping and amplicon sequencing with chromatograms, FASTA and BLAST reports.
NGS & Genomics
In-house library prep for WGS, WES, transcriptomics and metagenomics; high-throughput sequencing outsourced to partner NovaSeq X and DNBSEQ-T7 platforms, analysed in-house.
Bioinformatics
Variant calling & annotation, phylogenetics, microbiome analysis, protein structure prediction, custom pipelines.
ELISA & Immunoassays
Quantitative immunoassay development and testing for research and quality-control samples.
Cell-Based Bioassays
Relative potency, neutralization and binding assays for biologics and biosimilars — validated cell-based methods for release and comparability testing.
Clinical Cancer Genomics
Comprehensive genomic profiling, hereditary and tumor-specific panels with ACMG-classified clinical reporting.
Training & Contract Research
Molecular biology and bioinformatics workshops, custom assay development, outsourced R&D.
Precision oncology, from block to report
Whole exome sequencing analysis services that identify cancer-associated variants, hereditary cancer risk and actionable, precision-oncology findings.
Jump to the gene panel database ↓Download the Clinical Cancer Genomics brochure (PDF)
Genes covered include
Deliverables: variant summary, clinical significance, ACMG classification, literature-supported findings, risk assessment and therapeutic implications.
Sample reports
De-identified real case output. Click to preview.
Click a test to see what it covers.
Comprehensive Genomic Profiling (CGP)FFPE / BloodRs. 97,000–115,000
Sequences and analyzes 562 genes associated with solid tumors — SNVs, indels, CNVs, select fusions and genomic signatures, reported against an ACMG-aligned classification framework.
HRD-50 AnalysisFFPE / BloodRs. 100,000–116,000
Not a fixed gene panel — HRD is a genome-wide scarring signature. The Genomic Instability Score (GIS) combines three components measured across the genome:
LOH (loss of heterozygosity) + TAI (telomeric allelic imbalance) + LST (large-scale state transitions). A GIS ≥42 is reported HRD-positive.
Interpreted alongside BRCA1/BRCA2 mutation status to flag PARP-inhibitor and platinum-chemotherapy sensitivity.
BRCA1 & BRCA2 AnalysisFFPE / BloodRs. 98,000–114,000
Genes: BRCA1, BRCA2. Full coding-region and splice-site coverage for germline or somatic pathogenic variants informing hereditary breast/ovarian cancer risk and PARP-inhibitor eligibility.
Microsatellite Instability (MSI)FFPE / BloodRs. 112,000–130,000
Mismatch-repair genes assessed: MLH1, MSH2, MSH6, PMS2 (plus the EPCAM regulatory region). Identifies MSI-High / dMMR tumors eligible for checkpoint-inhibitor immunotherapy.
Tumor Mutational Burden (TMB)FFPE / BloodRs. 117,000–135,000
Computed genome-wide from the sequencing data (mutations per megabase) rather than a fixed gene list — high TMB is an independent biomarker for immune checkpoint inhibitor response.
Germline Hereditary Cancer PanelBloodRs. 120,000
Clinically actionable hereditary cancer genes selected per NCCN hereditary testing criteria, including BRCA1, BRCA2, TP53, PALB2, ATM, CHEK2, MLH1, MSH2, MSH6, PMS2, APC, MUTYH, PTEN, STK11, CDH1 and others.
Precision Oncology Clinical ReportFFPE TissueRs. 147,000
Not a standalone test — a synthesized clinical report integrating CGP, HRD and biomarker findings (MSI, TMB) into a single ACMG-classified, therapy-oriented summary for the treating oncologist.
Tumor-type genomic panels (lung, breast, ovarian, colorectal, pancreatic, prostate, gastric, melanoma) — Rs. 145,000 each, FFPE tissue, 5-week TAT.
Sample reports
Real NCRO case output, de-identified — all patient, physician and institution details removed. Shown to illustrate report depth and format; click a case to expand.
Case A — High-Grade Serous Carcinoma CGP + HRD · FFPE & Blood PIK3CA positive · HRD positive
CGP — FFPE tissue, DNA WES, average coverage 89.03x. Genes tested: BRAF, BRCA1, BRCA2, BRIP1, CHEK1, CHEK2, PALB2, RAD51C, RAD51D, TP53 — all negative.
| Gene | Mutation | VAF | Significance |
|---|---|---|---|
| PIK3CA | c.G1798A (p.E600K) | 15.5% (het) | Pathogenic |
COSMIC ID COSV55891897 — observed in endometrium, cervix and bladder carcinoma samples.
Additional VUS
| Gene | Mutation | VAF | Significance |
|---|---|---|---|
| GNAS | c.G2531A (p.R844H) | 24.8% (het) | Likely Pathogenic |
COSMIC ID COSV55670349 — observed in ovarian carcinoma/adenoma/borderline tumors, plus thyroid, soft tissue, small intestine and pituitary cancers.
HRD — Peripheral blood, DNA WES. Status: POSITIVE — GIS 95/100 (threshold ≥42). LOH 41 · TAI 32 · LST 22.
Case B — Peritoneal / Omental Deposit HRD only · Blood (EDTA) HRD positive
HRD — Peripheral blood in EDTA, DNA WES via Agilent SureSelect Human All Exon V6 library prep, sequenced on BGI DNBSEQ; HRD status determined via scarHRD.
Status: POSITIVE — GIS 69/100 (threshold ≥42). LOH 15 · TAI 21 · LST 33.
Case C — Serous Carcinoma CGP + HRD · Blood No pathogenic CGP findings · HRD positive
CGP — Peripheral blood, DNA WES (Agilent SureSelect Human All Exon V6 + BGISEQ), average coverage 130.6x. Genes tested: BRAF, BRCA1, BRCA2, BRIP1, CHEK1, CHEK2, PALB2, RAD51C, RAD51D, PIK3CA, TP53 — all negative.
Variants of uncertain significance
| Gene | Mutation | VAF | Significance |
|---|---|---|---|
| BAP1 | c.1408G>A (p.G470R) | 42.46% (het) | Uncertain significance |
| FLCN | c.1333G>A (p.A445T) | 47.6% (het) | Uncertain significance |
BAP1: BAP1 tumor predisposition syndrome (ClinVar 133663 / dbSNP rs576538858). FLCN: Birt-Hogg-Dubé syndrome, colorectal cancer (ClinVar 3370 / dbSNP rs41419545).
HRD — Peripheral blood, DNA WES. Status: POSITIVE — GIS 51/100 (threshold ≥42). LOH 7 · TAI 13 · LST 31.
Sample collection
Patient blood or tissue received
DNA extraction & QC
High-quality DNA extracted and evaluated
Whole exome sequencing
All protein-coding regions sequenced
Bioinformatics analysis
Computational variant identification
Clinical interpretation
Variant annotation, significance assessment
Comprehensive reporting
Customized report per client requirements
Whole blood (germline)
- 3–5 mL peripheral blood
- EDTA (purple-top) tube
- Store at 2–8°C
- Ship within 48 hours
FFPE tissue (block)
- Submit clearly labeled block
- Include pathology report if available
- Somatic variant / solid tumor profiling
Fresh tissue
- Sterile container
- Keep chilled, 2–8°C
- Ship immediately
- Avoid freeze-thaw cycles
Purified DNA
- ≥500 ng high-quality genomic DNA
- A260/A280 ratio 1.8–2.0
- Concentration ≥20 ng/µL
Search the gene panel database
4,953 unique genes across NCRO's nine curated panels — PanCancer Pro, Hemato Pro, Neoscreen Pro, Cardio Pro, ClinEX Pro, Fusion Pro, Heva Pro, HRD Pro and IVF Pro — each with its clinical or research significance and, where one exists, the FDA-approved drug or NCCN-aligned clinical management implication. A gene relevant to more than one panel is listed once, with the panel-specific significance merged in. Want to build a custom Sanger, PCR or NGS order around specific genes or exons, or get an instant priced quote? Visit NCRO Biotools (login required).
Drug and clinical-management information reflects FDA approvals and NCCN-aligned practice at the time of writing and is for reference only — always confirm current guidance and eligibility with the treating oncologist.
AMR Gene Panel
Detect today. Treat right. Protect tomorrow. A conventional PCR-based panel detecting a wide range of antimicrobial resistance genes across major bacterial pathogens — covering beta-lactams, carbapenems, aminoglycosides, fluoroquinolones, macrolides, tetracyclines and sulfonamides, including ESBL, AmpC, carbapenemase and MBL resistance genes.
NCRO-MBA-AMR12 · 12-gene PCR assay · Rs. 26,000
Download the AMR Gene Panel brochure (PDF)Better decisions.
Better outcomes.
AMR gene & species database
43 antimicrobial resistance genes spanning ESBL, AmpC, carbapenemase/MBL, aminoglycoside, fluoroquinolone, macrolide, tetracycline, sulfonamide, glycopeptide/MRSA and colistin resistance mechanisms, mapped to the organisms they're most commonly found in.
Species listed reflect the organisms this gene is most commonly detected in — not an exhaustive host range. Panel composition can be tailored per client (clinical, food safety or environmental surveillance use case).
Cell-based potency & bioassay services
Relative potency testing for biologics and biosimilars, run as validated cell-based assays with tiered sample packages. Custom assay development available for other molecules.
Jump to the biologics database ↓Adalimumab
TNF-α neutralization assay| Package 1 · 1 sample | Rs. 810,000 |
| Package 2 · 2 samples | Rs. 815,000 |
| Package 3 · 3 samples | Rs. 1,100,000 |
Trastuzumab
BT-474 anti-proliferation assay| Package 1 · 1 sample | Rs. 805,000 |
| Package 2 · 2 samples | Rs. 810,000 |
| Package 3 · 3 samples | Rs. 1,090,000 |
Rituximab
Complement dependent cytotoxicity (CDC)| Package 1 · 1 sample | Rs. 1,575,000 |
| Package 2 · 2 samples | Rs. 1,600,000 |
| Package 3 · 3 samples | Rs. 2,135,000 |
Bevacizumab
VEGF neutralization assay| Package 1 · 1 sample | Rs. 825,000 |
| Package 2 · 2 samples | Rs. 830,000 |
| Package 3 · 3 samples | Rs. 1,111,000 |
Packages are priced per sample set (samples + reference standard, run in triplicate). Turnaround and payment terms confirmed at quotation stage.
Biologics potency assay database
60 innovator biologics and their approved biosimilars, organized by drug class, with the test method and generic reference cell line for each — brand-agnostic, so it reflects what's biologically being tested rather than a specific reagent vendor. Search or filter by class to check what we can run.
Reference cell lines are generic/brand-agnostic (e.g. GenScript catalog IDs), listed only where a validated line is available; most classes are run as custom cell-based potency assays. Not all molecules are stock-held — confirm availability when requesting a quote.
Search the service catalogue
Every listed service carries its own catalogue number, unit and indicative price — search or filter by category to find what you need.
Prices in PKR, exclusive of applicable sales tax. Volume, panel and multi-sample pricing available on request — request a formal quotation.
Resource library
Brochures and de-identified sample reports — browse or download directly. Search to filter by name or category.
Need something that isn't listed — a proposal, an SLA, a custom panel spec? Request it here and we'll send it over.
Built for four industries
Research & academia
Universities and institutes running genomics, molecular biology and bioinformatics projects.
Healthcare
Hospitals and clinics referring hereditary, infectious disease and oncology molecular testing.
Biopharma & biotech
Potency, comparability and characterization testing for biologics and biosimilars.
Agrifood & environment
Pathogen panels, GMO detection, food safety and environmental molecular testing.
From email to report
Send your brief
Email us a short overview of the project or sample you need tested.
Scientific assessment
Our PhD-level team reviews it and prepares a proposal.
Consultation
We meet to discuss the proposal and finalize scope.
Sample submission
Samples are shipped or collected per our logistics guidance.
Testing & analysis
Assay, sequencing and bioinformatics work is carried out.
Report delivered
A reviewed, actionable report is sent to your team.
Used by more than 100 groups
"We have utilized this group's services and have always felt satisfied with the results."
Prof. Dr. Khan"Wonderful service — on time and on budget. We recommend this service to anyone interested in serious and quality research."
Prof. NiaziBook a free consultation
Send us a brief overview of your project — our scientific team will review it and get back with a proposal.